Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.

J Clin Pharmacol · 2021 · PMC7754485 · PMID 32696522

Europe PMC DOI

hedged sentences

0.0000

closest p · 0.0× alpha

0.0538

boldest claim

The sentences

highly significantP < .00001actually significant

This difference was highly significant when comparing each AUC avg group with placebo group ( P < .00001, Tukey test).

also in 132,142 other papers

marginally significantP = .0538so close (0.05 < p ≤ 0.1)

In the Cox proportional hazards regression analysis for luspatercept‐treated patients (Table 4 ), the exposure‐associated reduction in TEAEs was marginally significant ( P = .0538) for TEAEs ≥ grade 3 and statistically significant for bone pain ≥ grade 1 ( P = .0153) after adjusting for the effects of baseline risk factors.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.